CFM
ALNY icon

Catalyst Funds Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Catalyst Funds Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.26M Buy
+20,803
New +$6.27M 0.35% 78
2025
Q4 		– Sell
-8,320
Closed -$3.79M – 341
2025
Q3 		$3.79M Sell
8,320
-2,450
-23% -$998K 0.57% 31
2025
Q2 		$3.51M Sell
10,770
-8,430
-44% -$2.33M 0.97% 15
2025
Q1 		$5.18M Buy
+19,200
New +$4.93M 1.36% 8

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Funds Management's ALNY Position: Q2 2026 in Review

Catalyst Funds Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 20,803 shares worth $6.26M. The stake represents 0.35% of the portfolio and ranks #78 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in ALNY as recently as Q3 2025.

Catalyst Funds Management first reported a position in ALNY in Q1 2025 and has held it in 4 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Catalyst Funds Management held 20,803 shares of Alnylam Pharmaceuticals worth $6.26M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Catalyst Funds Management position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.35% of Catalyst Funds Management's portfolio in Q2 2026, its #78 holding.
  • Catalyst Funds Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.